Muraglitazar (Bristol-Myers Squibb/Merck)

Current Opinion in Investigational Drugs

Volumn 6, Issue 4, 2005, Pages 427-434

  Barlocco, Daniela ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ACYL COENZYME A; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; APOLIPOPROTEIN C3; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CORTICOSTERONE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FATTY ACID; FUROSEMIDE; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BODY WEIGHT DISORDER; CARCINOGENESIS; CELL STRAIN CACO 2; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORTICOSTERONE BLOOD LEVEL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FASTING BLOOD GLUCOSE; FLUID RETENTION; FLUORESCENCE POLARIZATION; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART EDEMA; HUMAN; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MONOTHERAPY; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATENT; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; DRUG INDUSTRY; GLYCINE; HUMANS; HYPOGLYCEMIC AGENTS; OXAZOLES; PPAR ALPHA; PPAR GAMMA;

EID: 17644363341     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. 419773 Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPAR-α, PPAR-γ and PPAR-δ. Liu KG, Smith JS, Ayscue AH, Henke BR, Lambert MH, Leesnitzer LM, Plunket KD, Willson TM, Sternbach DD BIOORG MED CHEM LETT 2001 11 17 2385-2388
2. 442540 Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K STRUCTURE 2001 9 8 699-706
3. 454098 BMS-298585 is a novel, uniquely balanced dual activator of peroxisome proliferator activated receptors (PPAR) α and γ, with an excellent ADME profile. Cheng PT, Chandrasena G, Chen S, Devasthale P, Hariharan N DIABETES 2002 51 2 A381-PO
4. 454180 BMS-298585, a novel uniquely balanced dual activator of PPAR α and γ, shows robust glucose and lipid lowering effects in genetic and diet induced diabetic and hyperlipidemic mouse models. Hariharan N, Chen S, Cheng P, Chu C, Devasthale P, Farrelly D, Harrity T, Selan F DIABETES 2002 51 2 A405-P
5. 454181 BMS-298585, a novel uniquely balanced dual activator of PPAR α and γ, shows robust lipid and glucose lowering effects in high fat diet induced hyperlipidemic insulin resistant hamsters. Harrity T, Hariharan N, Chang P, Selan F, Kunselman L, Chen S, Devasthale P, Chu C, Farrelly D DIABETES 2002 51 2 A407-P
6. 454850 American Diabetes Association - 62nd Scientific Sessions (Part II) - Overnight Report, San Francisco, CA, USA. Mackay J IDDB MEETING REPORT 2002 June 14-18
7. 463529 BMS-298585, a novel uniquely balanced duel agonist of PPAR α and γ, lowers lipid in diet induced diabetic and hyperlipidemic mice and hamsters. Hariharan N, Harrity T, Kunselman L, Farrelly D, Sasseville V, Cheng PT DIABETOLOGIA 2002 45 Suppl 2 A234
8. 472881 Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators. Heidrich J, Jendeberg L, Lindqvist B, Pegurier C, Roussel P, Slater M, Svensson S, Sydow-Backman M, Thomstrom U, Uppenberg J BIOORG MED CHEM LETT 2002 12 24 3565-3567
9. 478168 Novo Nordisk to move forward on development of Dr Reddy's balaglitazone - DRF 2593. Dr Reddy's Laboratories Ltd PRESS RELEASE 2003 February 06
10. 478217 Novo Nordisk A/S (NYSE: NVO) financial statement for 2002. Novo Nordisk A/S PRESS RELEASE 2003 February 06
11. 480939 Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM PROC NATL ACAD SCI USA 2001 98 24 13919-13924
12. 484817 Amphipathic 3-phenyl-7-propylbenzisoxazoles; human PPAR γ, δ and α agonists. Adams AD, Yuen W, Hu Z, Santini C, Jones AB, MacNaul KL, Berger JP, Doebber TW, Moller DE BIOORG MED CHEM LETT 2003 13 5 931-935
13. 486672 Annual Report 2002: Bristol-Myers Squibb. Bristol Myers Squibb Co ANNUAL REPORT 2003 March 25
14. 514245 Merck discontinues development of MK-767 for diabetes. Merck & Co Inc PRESS RELEASE 2003 November 20
15. 525071 Bristol-Myers Squibb: Development compounds. Bristol Myers Squibb Co COMPANY WORLD WIDE WEB SITE 2004 February 12
16. 535305 Bristol-Myers Squibb and Merck announce global development and commercialization alliance for muraglitazar, a novel compound for diabetes. Bristol-Myers Squibb Company PRESS RELEASE 2004 April 28
17. 535435 Merck & Co enters alliance for BMS's diabetes drug muraglitazar. Merck & Co Inc PRESS RELEASE 2004 April 28
18. 541486 Muraglitazar, a novel non-TZD dual PPAR α/γ agonist, improves metabolic abnormalities in obese, severely diabetic db/db mice. Harrity T, Chu C, Kunselman L, Ponticiello R, Cap M, Cheng P, Hariharan N DIABETES 2004 53 Abs 134-OR
19. 541493 Glucose lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPAR α /γ dual agonist, in type 2 diabetic patients. Mosqueda-Garcia R, Frost CE, Swaminathan A, Raymond R, Nepal S, Reeves R, Gregg R DIABETES 2004 53 Abs 138-OR
20. 542286 Muraglitazar, a novel non-TZD PPAR α/γ dual agonist, regulates genes involved in reverse cholesterol transport, stimulates cholesterol efflux, and reduces MCP1 secretion in human THP1 macrophage cells. Zhou M, Peters A, Cao G, Farrelly D, Harrity T, Cheng P, Hariharan N DIABETES 2004 53 Abs 640-P
21. 542450 American Diabetes Association - 64th Scientific Sessions (Part III) - Overnight Report, Orlando, FL, USA. Mazucco R IDDB MEETING REPORT 2004 June 4-8
22. 542466 Pharmacokinetics of single doses of the novel PPAR α/γ dual agonist muraglitazar (BMS-298585) in healthy human subjects. Swaminathan A, Frost CE, Raymond R, Reeves R, Mosqueda-Garcia R DIABETES 2004 53 Abs 618-P
23. 544834 Lipid lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPAR α/γ dual agonist, in type 2 diabetic patients. Frost CE, Swaminathan A, Raymond R, Nepal S, Gregg R, Reeves R, Mosqueda-Garcia R DIABETES 2004 53 Abs 1988-PO
24. 571507 BMS provides R&D update. Bristol-Myers Squibb Co PRESS RELEASE 2004 November 17
25. 572056 Bristol-Myers Squibb R&D review. Bristol-Myers Squibb Co COMPANY PRESENTATION 2004 November 17
26. 577532 BMS submits muraglitazar NDA for type 2 diabetes. Bristol-Myers Squibb Co PRESS RELEASE 2004 December 23
27. 579204 Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes. Henke BR J MED CHEM 2004 47 17 4118-4127
28. 579206 Future targets in the treatment of type 2 diabetes. Stingl H, Roden M WIEN KLIN WOCHENSCHR 2004 116 7-8 217-229.
29. 579210 PPARs and the complex journey to obesity. Evans RM, Barish GD, Wang Y-X NAT MED 2004 10 4 355-361
30. 579213 Identification of potent PPARα agonists. Sauerberg P, Mogensen JP, Jeppese L, Fleckner J, Wulff EM, Nehlin J, Pettersson I DRUGS FUTURE 2004 29 Suppl A P191
31. 579216 Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes. Ram VJ DRUGS TODAY 2003 39 8 609-632
32. 579218 The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity. Ferre P DIABETES 2004 53 Suppl 1 S43-S50
33. 579221 Pharmaceutical approaches to the treatment of obesity. Jandacek, RJ, Woods SC DRUG DISC TODAY 2004 9 20 874-880
34. 579457 Potential role of peroxisome proliferator-activated receptor-α in the modulation of glucose-stimulated insulin secretion. Sugden MC, Holness MJ DIABETES 2004 53 Suppl 1 S71-S81
35. 579458 Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Rangwala SM, Lazar MA TRENDS PHARMACOL SCI 2004 25 6331-336
36. 579459 Virtual docking of 2-phenylthio-2-(methyl)propanoic acid derivatives: Insights into new selective PPARα agonists. Gallo G, Tinti MO, Carminati P, Giannessi F, Dell'Uomo N, Milazzo FM, Sciarroni AF, Floravanzo E, Ciacci A DRUGS FUTURE 2004 29 Suppl A P258
37. 579461 The role of PPARs in obesity and other insulin resistance associated disorders. Chakrabarti R, Rajagopalan R CURR MED CHEM - IMMUNOL ENDOCRINE METAB AGENTS 2004 4 2 67-73
38. 579463 Clinical interest of PPARs ligands: Particular benefit in type 2 diabetes and metabolic syndrome. Verges B DIABETES METAB 2004 30 1 7-12
39. 579464 Synthesis of novel antidiabetic polymer containing thiazolidinedione and L-ascorbic acid. Jeon R, Lee SM DRUGS FUTURE 2004 29 Suppl A P250
40. 579465 In vitro and in vivo evaluation of selective peroxisomal proliferator-activated receptor γ modulators (SPPARγMs). Wood H, Acton J, Black R, Jones A, Mosley R, Mckeever BM, Becker JW, Johnson BA, Colwell L, Habilihaz B, Doebber T et al DRUGS FUTURE 2004 29 Suppl A P195
41. 579466 Synthesis and crystal structure of a PPAR pan agonist that delivers glycemic control and improved lipid profiles without weight gain. Sternbach DD, Rafferty S, Cadilla R, Lambert M, Xu E, Montana V, Oliver W Jr DRUGS FUTURE 2004 29 Suppl A 044
42. 579467 Adiponectin-adipocytokine with a broad clinical spectrum. Szopa M, Malczewska-Malec M, Wybranska I, Kiec-Wilk B, Bodzioch M, Trzos M, Dembinska-Kiec A PRZEGL LEK 2004 61 2 109-114
43. 579468 Diabetes, lipids, and adipocyte secretagogues. Faraj M, Lu HL, Cianflone K BIOCHEM CELL BIOL 2004 82 1 170-190
44. 579469 Genetics of diabetes. Horenstein RB, Shuldiner AR REV ENDOCRINE METAB DISORDERS 2004 5 1 25-36
45. 579473 Signals adapting the β cells to changes in insulin sensitivity. Ahren B, Pacini G INT CONGR SER EXCERPTA MED 2003 1253 105-113
46. 579474 Plasma adiponectin and hyperglycemia in diabetic patients. Mannucci E, Ognibene A, Cremasco F, Dicembrini I, Bardini G, Brogi M, Terreni A, Caldini A, Messeri G, Rotella CM CLIN CHEM LAB MED 2003 41 9 1131-1135
47. 579480 Peroxisome proliferator-activated receptor-γ. Too much of a good thing causes harm. Cock T-A, Houten SM, Auwerx J EMBO REPS 2004 5 2 142-147
48. 579481 Roles of peroxisome proliferator-activated receptors δ and γ in myoblast transdifferentiation. Holst D, Luquet S, Kristiansen K, Grimaldi PA EXP CELL RES 2003 288 1 168-176
49. 581315 Novartis shows dynamic momentum in industry-leading pipeline. Novartis AG PRESS RELEASE 2005 January 20
50. 587224 Glycemic treatment: Control of glycemia. Bloomgarden ZT DIABETES CARE 2004 27 5 1227-1234
51. 587229 Monocyte chemoattractant protein-1: Does it play a role in diabetic nephropathy? Wada T, Yokoyama H, Matsushima K, Kobayashi K NEPHROL DIAL TRANSPLANT 2003 18 3 457-459
52. 587231 Decreased osteoblast activity in spontaneously diabetic rats. In vivo studies on the pathogenesis. Verhaeghe J, Van Herck E, van Bree R, Moermans K, Bouillon R ENDOCRINE 1997 7 2 165-175
53. 3 and corticosterone found in experimental diabetes reduces nerve growth factor (NGF) gene expression in vitro. Neveu I, Jehan F, Wion D LIFE SCI 1992 50 23 1769-1772
54. 587234 Novel peroxisome proliferator-activated receptor ligands for type 2 diabetes and the metabolic syndrome. Miller AR, Etgen GJ EXP OPIN INVESTIG DRUGS 2003 12 9 1489-1500
55. 587237 Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl] ethoxy)phenoxy]propionic acids: A new class of dual PPARα/γ agonists. Brooks DA, Etgen GJ, Rito CJ, Shuker AJ, Dominianni SJ, Warshawsky AM, Ardecky R, Paterniti JR, Tyhonas J, Karanewsky DS, Kauffman RF et al J MED CHEM 2001 44 13 2061-2064
56. 587243 AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. Ljung B, Bamberg K, Dahllof B, Kjellstedt A, Oakes ND, Ostling J, Svensson L, Camejo G J LIPID RES 2002 43 11 1855-1863
57. 587365 A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ. Effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T DIABETES 1998 47 12 1841-1847
58. 587368 (2R)-2-Ethylchromane-2-carboxylic acids: Discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents. Doebber TW, Wu MS, Zhou G, Wang PR, Ippolito MC, Chao YS, Agrawal AK, Franklin R, Heck JV, Wright SD, Moller DE, Sahoo SP J MED CHEM 2004 47 12 3255-3263
59. 587372 Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF MOL PHARMACOL 2005 67 1 69-77
60. 587374 An overview on biological mechanisms of PPARs. Kota BP, Huang TH, Roufogalis BD PHARMACOL RES 2005 51 2 85-94
61. 587375 Up-regulation of PPARγ coactivator-1α as a strategy for preventing and reversing insulin resistance and obesity. McCarty MF MED HYPOTHESES 2005 64 2 399-407
62. 587658 Role of glucocorticoids in mediating effects of fasting and diabetes on hypothalamic gene expression. Makimura H, Mizuno TM, Isoda F, Beasley J, Silverstein JH, Mobbs CV BMC PHYSIOL 3 1 5
63. 588268 (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Juluri S, Mamidi NV, Rajagopalan R J MED CHEM 2001 44 14 2675-2678
64. 588299 Merck & Co. Arnold CJ, Gordon MI CREDIT SUISSE FIRST BOSTON 2005 February 22